Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS

Olaparib, an orally active inhibitor of poly(ADP-ribose)polymerase(PARP), is the drug of choice in the treatment of gBRCA1/2+ metastatic breast cancers. Unfortunately, Olaparib is poorly soluble with low bioavailability and tumor accumulation; nano-delivery could be a good choice to overcome these d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottria, Roberta, Ravelli, Alessandro, Miceli, Matteo, Casati, Sara, Orioli, Marica, Ciuffreda, Pierangela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429415/
https://www.ncbi.nlm.nih.gov/pubmed/30862103
http://dx.doi.org/10.3390/molecules24050989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429415/
https://www.ncbi.nlm.nih.gov/pubmed/30862103
http://dx.doi.org/10.3390/molecules24050989

Ejemplares similares